• Successful transition to clinical-stage cell therapy company
• Received US FDA clearance for ALA-101
• Expanded platform into solid tumours and autoimmune diseases
• Strengthened clinical and scientific leadership
• Board renewal with new directors

Arovella Therapeutics Ltd. reported a successful transition to a clinical-stage cell therapy company in FY2026. The company achieved key milestones including US FDA clearance for its lead product, ALA-101, a CD19-directed CAR-iNKT cell therapy. Arovella also expanded its platform into solid tumours and autoimmune diseases, demonstrating potential in preclinical models. The company strengthened its clinical and scientific leadership and completed a board renewal with the appointment of three new directors. Arovella's strategy focuses on building a modular CAR-iNKT platform with potential applications across various cancer types and autoimmune diseases.

Arovella anticipates the initiation of its first-in-human study for ALA-101 and the generation of clinical data, which could expand the platform into solid tumours and autoimmune diseases.